Literature DB >> 14597161

Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.

Kathryn L Armour1, Jan G J van de Winkel, Lorna M Williamson, Mike R Clark.   

Abstract

We are investigating the interactions of recombinant human IgG antibodies with Fc receptors to enable selection of a constant region giving minimal depletion of antigen-bearing cells. Eight variant constant regions were made by substituting motifs between human IgG subclasses in the lower hinge region and/or a specially close loop of the CH2 domain. Mutations in the lower hinge region were shown to eliminate FcgammaRI binding and monocyte activation [Eur. J. Immunol. 29 (1999) 2613]. Here, we detail interactions with FcgammaRIIa of the 131R and 131H allotypes and FcgammaRIIb. Lower hinge mutations caused large reductions in binding whereas modification of residues 327, 330 and 331 had less dramatic effects. However, like the wildtype IgG subclass binding hierarchies, the effect of the mutations varied between different receptors. We identified IgG1 variants which react with the activating receptor, FcgammaRIIa, at least 10-fold less efficiently than wildtype IgG1 but whose binding to the inhibitory receptor, FcgammaRIIb, is only four-fold reduced. Manipulation of interactions with FcgammaRIIb separately from those with activating receptors provides potential for designing antibodies with novel and effective combinations of attributes. In addition, insight is gained into the evolution of functional differences in human IgG subclasses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597161     DOI: 10.1016/j.molimm.2003.08.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  27 in total

Review 1.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  IgG2m4, an engineered antibody isotype with reduced Fc function.

Authors:  Zhiqiang An; Gail Forrest; Renee Moore; Michael Cukan; Peter Haytko; Lingyi Huang; Salvatore Vitelli; Jing Zhang Zhao; Ping Lu; Jin Hua; Christopher R Gibson; Barrett R Harvey; Donna Montgomery; Dennis Zaller; Fubao Wang; William Strohl
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

3.  Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers.

Authors:  Cedric Ghevaert; Nina Herbert; Louise Hawkins; Nicola Grehan; Philip Cookson; Steve F Garner; Abigail Crisp-Hihn; Paul Lloyd-Evans; Amanda Evans; Kottekkattu Balan; Willem H Ouwehand; Kathryn L Armour; Mike R Clark; Lorna M Williamson
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

4.  5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.

Authors:  Alain Beck; Janice M Reichert; Thierry Wurch
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

5.  CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation.

Authors:  Maryam Rashidi; Esther Bandala-Sanchez; Kate E Lawlor; Yuxia Zhang; Alana M Neale; Swarna L Vijayaraj; Robert O'Donoghue; John M Wentworth; Timothy E Adams; James E Vince; Leonard C Harrison
Journal:  Cell Death Differ       Date:  2017-12-15       Impact factor: 15.828

6.  Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes.

Authors:  Qinglai Meng; Asifa K Zaidi; John Sedy; Armand Bensussan; Daniel L Popkin
Journal:  J Immunol       Date:  2019-02-15       Impact factor: 5.422

7.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

Authors:  Adam M Boruchov; Glenn Heller; Maria-Concetta Veri; Ezio Bonvini; Jeffrey V Ravetch; James W Young
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

8.  Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.

Authors:  Jin-Dong Ding; Lincoln V Johnson; Rolf Herrmann; Sina Farsiu; Stephanie G Smith; Marybeth Groelle; Brian E Mace; Patrick Sullivan; Jeffrey A Jamison; Una Kelly; Ons Harrabi; Sangeetha Subbarao Bollini; Jeanette Dilley; Dione Kobayashi; Bing Kuang; Wenlin Li; Jaume Pons; John C Lin; Catherine Bowes Rickman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

9.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

10.  T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.

Authors:  Esther Bandala-Sanchez; Yuxia Zhang; Simone Reinwald; James A Dromey; Bo-Han Lee; Junyan Qian; Ralph M Böhmer; Leonard C Harrison
Journal:  Nat Immunol       Date:  2013-05-19       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.